Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 130 resultater
Tid
Selskap
Tittel
Sektor
Kategori
23 Sep 2024
07:30 CEST
GENFIT
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
20103010 Biotechnology
Other subject
23 Sep 2024
07:30 CEST
GENFIT
GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine
20103010 Biotechnology
Other subject
19 Sep 2024
22:10 CEST
GENFIT
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
20103010 Biotechnology
Other subject
19 Sep 2024
22:10 CEST
GENFIT
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
20103010 Biotechnology
Other subject
26 Jul 2024
13:45 CEST
GENFIT
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
20103010 Biotechnology
Other subject
26 Jul 2024
13:45 CEST
GENFIT
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
20103010 Biotechnology
Other subject
09 Jul 2024
22:10 CEST
GENFIT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
09 Jul 2024
22:10 CEST
GENFIT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
17 Jun 2024
22:10 CEST
GENFIT
GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque
20103010 Biotechnology
Other subject
17 Jun 2024
22:10 CEST
GENFIT
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
20103010 Biotechnology
Other subject
10 Jun 2024
23:22 CEST
GENFIT
GENFIT : Étape historique franchie avec l'approbation accélérée d'Iqirvo® d’Ipsen dans la Cholangite Biliaire Primitive par la FDA américaine
20103010 Biotechnology
Other subject
10 Jun 2024
23:22 CEST
GENFIT
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
20103010 Biotechnology
Other subject
29 May 2024
22:10 CEST
GENFIT
GENFIT présentera ses dernières avancées dans l'ACLF à l'EASL Congress™ 2024
20103010 Biotechnology
Other subject
29 May 2024
22:10 CEST
GENFIT
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
20103010 Biotechnology
Other subject
22 May 2024
18:05 CEST
GENFIT
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
20103010 Biotechnology
General meeting / Board Meeting
22 May 2024
18:05 CEST
GENFIT
GENFIT : Résultats de l’Assemblée Générale Mixte du 22 mai 2024
20103010 Biotechnology
General meeting / Board Meeting
14 May 2024
22:10 CEST
GENFIT
GENFIT Reports First Quarter 2024 Financial Information
20103010 Biotechnology
Other subject
14 May 2024
22:10 CEST
GENFIT
GENFIT : Information financière du premier trimestre 2024
20103010 Biotechnology
Other subject
25 Apr 2024
22:10 CEST
GENFIT
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
20103010 Biotechnology
Other subject
25 Apr 2024
22:10 CEST
GENFIT
GENFIT : Publication du rapport de performance extra-financière 2024 (exercice 2023)
20103010 Biotechnology
Other subject
15 Apr 2024
22:10 CEST
GENFIT
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
15 Apr 2024
22:10 CEST
GENFIT
GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
05 Apr 2024
20:00 CEST
GENFIT
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
20103010 Biotechnology
Other subject
05 Apr 2024
20:00 CEST
GENFIT
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023
20103010 Biotechnology
Other subject
04 Apr 2024
22:10 CEST
GENFIT
GENFIT : Résultats financiers annuels 2023 et point sur les activités de la Société
20103010 Biotechnology
Other subject
04 Apr 2024
22:10 CEST
GENFIT
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
20103010 Biotechnology
Other subject
29 Feb 2024
22:10 CET
GENFIT
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023
20103010 Biotechnology
Other subject
29 Feb 2024
22:10 CET
GENFIT
GENFIT Announces Revenues and Cash Position as of December 31, 2023
20103010 Biotechnology
Other subject
15 Jan 2024
22:10 CET
GENFIT
GENFIT annonce son calendrier financier pour 2024
20103010 Biotechnology
Other subject
15 Jan 2024
22:10 CET
GENFIT
GENFIT Announces 2024 Financial Calendar
20103010 Biotechnology
Other subject
11 Jan 2024
22:10 CET
GENFIT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
11 Jan 2024
22:10 CET
GENFIT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
20103010 Biotechnology
Other subject
08 Dec 2023
07:55 CET
GENFIT
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
20103010 Biotechnology
Other subject
08 Dec 2023
07:55 CET
GENFIT
GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de demandes d’autorisation d’élafibranor dans la Cholangite Biliaire Primitive (PBC)
20103010 Biotechnology
Other subject
07 Dec 2023
11:15 CET
GENFIT
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
20103010 Biotechnology
Other subject
07 Dec 2023
11:15 CET
GENFIT
Ipsen confirme la décision de la FDA d'accorder un examen prioritaire pour le dépôt du dossier de demande d'autorisation d'elafibranor dans le traitement de la cholangite biliaire primitive, une maladie cholestatique rare du foie
20103010 Biotechnology
Other subject
06 Dec 2023
17:30 CET
GENFIT
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
20103010 Biotechnology
Other subject
06 Dec 2023
17:30 CET
GENFIT
GENFIT annonce une publication dans le Journal of Hepatology sur la performance et la précision de NIS2+™ en tant qu’outil de screening pour le recrutement des patients dans les essais cliniques MASH
20103010 Biotechnology
Other subject
16 Nov 2023
22:10 CET
GENFIT
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
20103010 Biotechnology
Other subject
16 Nov 2023
22:10 CET
GENFIT
GENFIT dévoile sa stratégie de développement dans l’ACLF lors de son « ACLF Day » organisé dans le cadre du congrès de l’AASLD The Liver Meeting® 2023
20103010 Biotechnology
Other subject
13 Nov 2023
22:30 CET
GENFIT
GENFIT : Les résultats de l’essai pivot de Phase III ELATIVE® d’Ipsen avec élafibranor dans la PBC présentés comme données de dernière minute au congrès de l’AASLD et publiés dans le New England Journal of Medicine
20103010 Biotechnology
Other subject
13 Nov 2023
22:30 CET
GENFIT
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
20103010 Biotechnology
Other subject
09 Nov 2023
22:10 CET
GENFIT
GENFIT : Information financière du troisième trimestre 2023
20103010 Biotechnology
Other subject
09 Nov 2023
22:10 CET
GENFIT
GENFIT Reports Third Quarter 2023 Financial Information
20103010 Biotechnology
Other subject
02 Nov 2023
22:10 CET
GENFIT
GENFIT présente ses avancées scientifiques et stratégiques au congrès international The Liver Meeting® 2023
20103010 Biotechnology
Other subject
02 Nov 2023
22:10 CET
GENFIT
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
20103010 Biotechnology
Other subject
26 Sep 2023
22:10 CEST
GENFIT
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
20103010 Biotechnology
Other subject
26 Sep 2023
22:10 CEST
GENFIT
GENFIT annonce une publication dans Nature Medicine confirmant la performance de sa technologie de diagnostic dans la NASH
20103010 Biotechnology
Other subject
20 Sep 2023
22:10 CEST
GENFIT
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
20103010 Biotechnology
Other subject
20 Sep 2023
22:10 CEST
GENFIT
GENFIT : Résultats financiers du premier semestre 2023 et point sur les activités de la Société
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva